Categories: CancerNews

Tufts Medical Center Becomes First Hospital in Massachusetts to Adopt MOLLI Surgical’s Breast Cancer Technology

MOLLI® 2 System offers breast cancer patients unmatched surgical precision and enhanced comfort

BOSTON, July 18, 2024 /PRNewswire/ — MOLLI Surgical is proud to announce that breast surgeons at Tufts Medical Center, a leading academic medical center in Massachusetts, are adopting the MOLLI® 2 System. The technology is also being used at fellow Tufts Medicine site, MelroseWakefield Hospital. MOLLI Surgical’s wire-free and radiation-free technology for localizing lesions for breast cancer surgery improves the patient experience and has earned praise from surgeons for its accuracy and ease of use.

“At Tufts Medical Center, we are always searching for new innovations and technologies to provide an enhanced patient experience that doesn’t sacrifice efficiency and accuracy,” said Abhishek Chatterjee, MD, Chief of the Division of Plastic Surgery at Tufts Medical Center. “It’s always an added benefit when there is a seamless implementation that makes the transition easy for surgeons, radiologists and the surgical support team.”

The MOLLI 2 System is an innovative technology that allows radiologists to mark lesions with the MOLLI® Marker, a localization device roughly the size of a sesame seed. Surgeons then use the MOLLI® Wand and MOLLI® Tablet to locate the lesion marked in radiology reliably. The technology features a market-leading innovation — directional 3D guidance — which enables MOLLI 2 to direct surgeons to the lesion with millimeter precision. The MOLLI 2 System is easy to use, reliable, and precise, improving efficiency and enhancing the patient experience.

“Our goal in designing and building the MOLLI 2 System is to drastically improve the patient experience through simple, effective, and safe precision surgery technology,” said Ananth Ravi, President and CEO of MOLLI Surgical. “We’re thrilled to partner with Tufts Medical Center as we both share the same commitment to patients and providing innovative, best-in-class breast cancer treatment that keeps the patient experience at the forefront.”

This collaboration underscores the commitment of Tufts Medical Center and MOLLI Surgical to enabling precision surgery made simpler, elevating clinical efficiency, and enhancing the patient and physician experience.

About MOLLI Surgical:
MOLLI Surgical started with one patient, who asked if there was a way to make her breast cancer journey better. Her voice led to the creation of our flagship wire and radiation-free technologies — MOLLI® 2 and MOLLI re.markable™. Our innovations are intended to replace outdated procedures to mark lesions for surgical removal through greater precision, efficiency, and cost-effectiveness. We are obsessed with every detail of our design process to ensure surgeons and radiologists have the best possible tools to support an improved patient experience.

MOLLI® has been recognized by TIME as one of 2022’s “Best Inventions” in the Medical Care category and named to Fast Company’s list of “Next Big Things in Tech,” recognizing technological breakthroughs across industries that promise to transform the future. We are proud to build the advanced solutions that patients and physicians prefer. Follow us on Facebook, LinkedIn, X, and YouTube.

Press Contact:
Grace Halvorsen
gracehalvorsen@lightspeedpr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tufts-medical-center-becomes-first-hospital-in-massachusetts-to-adopt-molli-surgicals-breast-cancer-technology-302198646.html

SOURCE MOLLI Surgical

Staff

Recent Posts

TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS

LOS ANGELES, Dec. 5, 2025 /PRNewswire/ -- AI-generated deepfake scams are rapidly spreading across social media,…

53 minutes ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

4 hours ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

4 hours ago

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

7 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

7 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

7 hours ago